Dermatomyositis Drug Market, Global Outlook and Forecast 2022-2028
Report Code: KNJ1281553 No. of Pages: 74 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of Dermatomyositis Drug in global, including the following market information:
Global Dermatomyositis Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Dermatomyositis Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Dermatomyositis Drug companies in 2021 (%)
The global Dermatomyositis Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Abatacept Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Dermatomyositis Drug include MedImmune LLC, Neovacs SA, Novartis AG, Octapharma AG, Pfizer Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hope Pharmaceuticals Inc and Idera Pharmaceuticals Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Dermatomyositis Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dermatomyositis Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Dermatomyositis Drug Market Segment Percentages, by Type, 2021 (%)
Abatacept
Baricitinib
Dalazatide
Immune Globulin
IMO-8400
Others
Global Dermatomyositis Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Dermatomyositis Drug Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Dermatomyositis Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Dermatomyositis Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dermatomyositis Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Dermatomyositis Drug revenues share in global market, 2021 (%)
Key companies Dermatomyositis Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Dermatomyositis Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
MedImmune LLC
Neovacs SA
Novartis AG
Octapharma AG
Pfizer Inc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Hope Pharmaceuticals Inc
Idera Pharmaceuticals Inc
KPI Therapeutics Inc
Marathon Pharmaceuticals LLC
1 Introduction to Research & Analysis Reports
1.1 Dermatomyositis Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Dermatomyositis Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Dermatomyositis Drug Overall Market Size
2.1 Global Dermatomyositis Drug Market Size: 2021 VS 2028
2.2 Global Dermatomyositis Drug Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Dermatomyositis Drug Sales: 2017-2028
3 Company Landscape
3.1 Top Dermatomyositis Drug Players in Global Market
3.2 Top Global Dermatomyositis Drug Companies Ranked by Revenue
3.3 Global Dermatomyositis Drug Revenue by Companies
3.4 Global Dermatomyositis Drug Sales by Companies
3.5 Global Dermatomyositis Drug Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Dermatomyositis Drug Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Dermatomyositis Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Dermatomyositis Drug Players in Global Market
3.8.1 List of Global Tier 1 Dermatomyositis Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Dermatomyositis Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Dermatomyositis Drug Market Size Markets, 2021 & 2028
4.1.2 Abatacept
4.1.3 Baricitinib
4.1.4 Dalazatide
4.1.5 Immune Globulin
4.1.6 IMO-8400
4.1.7 Others
4.2 By Type - Global Dermatomyositis Drug Revenue & Forecasts
4.2.1 By Type - Global Dermatomyositis Drug Revenue, 2017-2022
4.2.2 By Type - Global Dermatomyositis Drug Revenue, 2023-2028
4.2.3 By Type - Global Dermatomyositis Drug Revenue Market Share, 2017-2028
4.3 By Type - Global Dermatomyositis Drug Sales & Forecasts
4.3.1 By Type - Global Dermatomyositis Drug Sales, 2017-2022
4.3.2 By Type - Global Dermatomyositis Drug Sales, 2023-2028
4.3.3 By Type - Global Dermatomyositis Drug Sales Market Share, 2017-2028
4.4 By Type - Global Dermatomyositis Drug Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Dermatomyositis Drug Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Dermatomyositis Drug Revenue & Forecasts
5.2.1 By Application - Global Dermatomyositis Drug Revenue, 2017-2022
5.2.2 By Application - Global Dermatomyositis Drug Revenue, 2023-2028
5.2.3 By Application - Global Dermatomyositis Drug Revenue Market Share, 2017-2028
5.3 By Application - Global Dermatomyositis Drug Sales & Forecasts
5.3.1 By Application - Global Dermatomyositis Drug Sales, 2017-2022
5.3.2 By Application - Global Dermatomyositis Drug Sales, 2023-2028
5.3.3 By Application - Global Dermatomyositis Drug Sales Market Share, 2017-2028
5.4 By Application - Global Dermatomyositis Drug Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Dermatomyositis Drug Market Size, 2021 & 2028
6.2 By Region - Global Dermatomyositis Drug Revenue & Forecasts
6.2.1 By Region - Global Dermatomyositis Drug Revenue, 2017-2022
6.2.2 By Region - Global Dermatomyositis Drug Revenue, 2023-2028
6.2.3 By Region - Global Dermatomyositis Drug Revenue Market Share, 2017-2028
6.3 By Region - Global Dermatomyositis Drug Sales & Forecasts
6.3.1 By Region - Global Dermatomyositis Drug Sales, 2017-2022
6.3.2 By Region - Global Dermatomyositis Drug Sales, 2023-2028
6.3.3 By Region - Global Dermatomyositis Drug Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Dermatomyositis Drug Revenue, 2017-2028
6.4.2 By Country - North America Dermatomyositis Drug Sales, 2017-2028
6.4.3 US Dermatomyositis Drug Market Size, 2017-2028
6.4.4 Canada Dermatomyositis Drug Market Size, 2017-2028
6.4.5 Mexico Dermatomyositis Drug Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Dermatomyositis Drug Revenue, 2017-2028
6.5.2 By Country - Europe Dermatomyositis Drug Sales, 2017-2028
6.5.3 Germany Dermatomyositis Drug Market Size, 2017-2028
6.5.4 France Dermatomyositis Drug Market Size, 2017-2028
6.5.5 U.K. Dermatomyositis Drug Market Size, 2017-2028
6.5.6 Italy Dermatomyositis Drug Market Size, 2017-2028
6.5.7 Russia Dermatomyositis Drug Market Size, 2017-2028
6.5.8 Nordic Countries Dermatomyositis Drug Market Size, 2017-2028
6.5.9 Benelux Dermatomyositis Drug Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Dermatomyositis Drug Revenue, 2017-2028
6.6.2 By Region - Asia Dermatomyositis Drug Sales, 2017-2028
6.6.3 China Dermatomyositis Drug Market Size, 2017-2028
6.6.4 Japan Dermatomyositis Drug Market Size, 2017-2028
6.6.5 South Korea Dermatomyositis Drug Market Size, 2017-2028
6.6.6 Southeast Asia Dermatomyositis Drug Market Size, 2017-2028
6.6.7 India Dermatomyositis Drug Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Dermatomyositis Drug Revenue, 2017-2028
6.7.2 By Country - South America Dermatomyositis Drug Sales, 2017-2028
6.7.3 Brazil Dermatomyositis Drug Market Size, 2017-2028
6.7.4 Argentina Dermatomyositis Drug Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Dermatomyositis Drug Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Dermatomyositis Drug Sales, 2017-2028
6.8.3 Turkey Dermatomyositis Drug Market Size, 2017-2028
6.8.4 Israel Dermatomyositis Drug Market Size, 2017-2028
6.8.5 Saudi Arabia Dermatomyositis Drug Market Size, 2017-2028
6.8.6 UAE Dermatomyositis Drug Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 MedImmune LLC
7.1.1 MedImmune LLC Corporate Summary
7.1.2 MedImmune LLC Business Overview
7.1.3 MedImmune LLC Dermatomyositis Drug Major Product Offerings
7.1.4 MedImmune LLC Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.1.5 MedImmune LLC Key News
7.2 Neovacs SA
7.2.1 Neovacs SA Corporate Summary
7.2.2 Neovacs SA Business Overview
7.2.3 Neovacs SA Dermatomyositis Drug Major Product Offerings
7.2.4 Neovacs SA Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.2.5 Neovacs SA Key News
7.3 Novartis AG
7.3.1 Novartis AG Corporate Summary
7.3.2 Novartis AG Business Overview
7.3.3 Novartis AG Dermatomyositis Drug Major Product Offerings
7.3.4 Novartis AG Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.3.5 Novartis AG Key News
7.4 Octapharma AG
7.4.1 Octapharma AG Corporate Summary
7.4.2 Octapharma AG Business Overview
7.4.3 Octapharma AG Dermatomyositis Drug Major Product Offerings
7.4.4 Octapharma AG Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.4.5 Octapharma AG Key News
7.5 Pfizer Inc
7.5.1 Pfizer Inc Corporate Summary
7.5.2 Pfizer Inc Business Overview
7.5.3 Pfizer Inc Dermatomyositis Drug Major Product Offerings
7.5.4 Pfizer Inc Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.5.5 Pfizer Inc Key News
7.6 Eli Lilly and Company
7.6.1 Eli Lilly and Company Corporate Summary
7.6.2 Eli Lilly and Company Business Overview
7.6.3 Eli Lilly and Company Dermatomyositis Drug Major Product Offerings
7.6.4 Eli Lilly and Company Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.6.5 Eli Lilly and Company Key News
7.7 F. Hoffmann-La Roche Ltd
7.7.1 F. Hoffmann-La Roche Ltd Corporate Summary
7.7.2 F. Hoffmann-La Roche Ltd Business Overview
7.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Major Product Offerings
7.7.4 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.7.5 F. Hoffmann-La Roche Ltd Key News
7.8 Hope Pharmaceuticals Inc
7.8.1 Hope Pharmaceuticals Inc Corporate Summary
7.8.2 Hope Pharmaceuticals Inc Business Overview
7.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Major Product Offerings
7.8.4 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.8.5 Hope Pharmaceuticals Inc Key News
7.9 Idera Pharmaceuticals Inc
7.9.1 Idera Pharmaceuticals Inc Corporate Summary
7.9.2 Idera Pharmaceuticals Inc Business Overview
7.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Major Product Offerings
7.9.4 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.9.5 Idera Pharmaceuticals Inc Key News
7.10 KPI Therapeutics Inc
7.10.1 KPI Therapeutics Inc Corporate Summary
7.10.2 KPI Therapeutics Inc Business Overview
7.10.3 KPI Therapeutics Inc Dermatomyositis Drug Major Product Offerings
7.10.4 KPI Therapeutics Inc Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.10.5 KPI Therapeutics Inc Key News
7.11 Marathon Pharmaceuticals LLC
7.11.1 Marathon Pharmaceuticals LLC Corporate Summary
7.11.2 Marathon Pharmaceuticals LLC Dermatomyositis Drug Business Overview
7.11.3 Marathon Pharmaceuticals LLC Dermatomyositis Drug Major Product Offerings
7.11.4 Marathon Pharmaceuticals LLC Dermatomyositis Drug Sales and Revenue in Global (2017-2022)
7.11.5 Marathon Pharmaceuticals LLC Key News
8 Global Dermatomyositis Drug Production Capacity, Analysis
8.1 Global Dermatomyositis Drug Production Capacity, 2017-2028
8.2 Dermatomyositis Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Dermatomyositis Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Dermatomyositis Drug Supply Chain Analysis
10.1 Dermatomyositis Drug Industry Value Chain
10.2 Dermatomyositis Drug Upstream Market
10.3 Dermatomyositis Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Dermatomyositis Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com